Corteva, Vylor Unveil Standalone Guidance After Spin-Off; Shares Diverge
CTVA is trading near its 52-week low of $11.84 (1.0% above the low) on elevated volume (9.2× avg).
Summary
Corteva completed its Vylor spin-off on Thursday, and Friday's trading shows a clear divergence: Vylor up 2.56% to $70.01, Corteva down 5.09% to $11.93. The article provides the first detailed standalone guidance for both companies. Corteva, now a pure-play crop protection firm, expects net sales to grow from $7.8B in 2026 to $8.4B-$8.7B by 2029, with EBITDA rising from $1.3B to $1.45B-$1.65B and margins exceeding 18%. Vylor, the seed and genetics business, targets 2029 net sales of $11.2B-$11.9B and EBITDA of $3.3B-$3.7B, backed by a $19B technology pipeline. This follows the spin-off's final legal clearance on October 1 and the first standalone financials filed the same day. The market's reaction suggests investors are reassessing Corteva's standalone value, with shares trading near their 52-week low.
At the time of this announcement, CTVA was trading at $11.96 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8B. The 52-week trading range was $11.84 to $90.97. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Benzinga.